Olmutinib‐induced palmoplantar keratoderma
暂无分享,去创建一个
M. Lacouture | Y. Sheen | C. Chu | C. Liang | K. L. Chen | C. W. Yang | Y. T. Cho | Y. Cho
[1] Esther S. Kim. Olmutinib: First Global Approval , 2016, Drugs.
[2] Chia‐Chi Lin,et al. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer. , 2016, JAMA dermatology.
[3] Inyoul Y. Lee,et al. A gain-of-function mutation in TRPV3 causes focal palmoplantar keratoderma in a Chinese family. , 2015, The Journal of investigative dermatology.
[4] D. Kelsell,et al. iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function. , 2014, Human molecular genetics.
[5] G. Barton,et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma , 2012, Nature Genetics.
[6] M. Alter,et al. The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[7] M. Lacouture,et al. Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. , 2010, Journal of the American Academy of Dermatology.
[8] J. English,et al. Acquired Palmoplantar Keratoderma , 2007, American journal of clinical dermatology.